indacaterol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 4183 312753-06-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • QAB149
  • QAB-149
  • QAB 149
  • indacaterol
  • Arcapta Neohaler
  • indacaterol maleate
Indacaterol is a long-acting beta2-adrenergic agonist. The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle.
  • Molecular weight: 392.50
  • Formula: C24H28N2O3
  • CLOGP: 2.97
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 81.59
  • ALOGS: -4.69
  • ROTB: 6

Drug dosage:

DoseUnitRoute
0.15 mg Inhal.powder

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 19.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.48 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.05 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 92.50 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 1, 2011 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic obstructive pulmonary disease 226.64 21.15 114 4847 57519 46623582
Dyspnoea 150.63 21.15 225 4736 515323 46165778
Lung neoplasm malignant 99.12 21.15 43 4918 15446 46665655
Wheezing 92.26 21.15 62 4899 53324 46627777
Cough 74.55 21.15 106 4855 230143 46450958
Asthma-chronic obstructive pulmonary disease overlap syndrome 70.05 21.15 15 4946 474 46680627
Respiratory failure 66.56 21.15 65 4896 94751 46586350
Total lung capacity increased 63.20 21.15 15 4946 759 46680342
Hyper IgE syndrome 62.77 21.15 12 4949 211 46680890
Nasal polyps 47.61 21.15 15 4946 2195 46678906
Bronchiectasis 44.18 21.15 21 4940 9295 46671806
Rhinitis allergic 43.59 21.15 19 4942 6889 46674212
Brain injury 42.37 21.15 18 4943 6132 46674969
Bronchospasm 41.70 21.15 24 4937 15683 46665418
Sputum discoloured 40.67 21.15 22 4939 12756 46668345
Asthmatic crisis 40.20 21.15 12 4949 1466 46679635
Pneumonia 39.76 21.15 108 4853 376212 46304889
Asthma 38.50 21.15 48 4913 91494 46589607
Obstructive airways disorder 36.96 21.15 21 4940 13391 46667710
Sarcoidosis 35.21 21.15 15 4946 5144 46675957
Cardiac failure 33.73 21.15 42 4919 79906 46601195
Restrictive pulmonary disease 33.55 21.15 10 4951 1216 46679885
Polycystic ovaries 32.35 21.15 10 4951 1374 46679727
Congestive cardiomyopathy 30.56 21.15 14 4947 5699 46675402
Paranoia 30.30 21.15 17 4944 10580 46670521
Left ventricular failure 29.14 21.15 13 4948 4977 46676124
Productive cough 26.96 21.15 30 4931 50685 46630416
Sleep disorder due to a general medical condition 26.64 21.15 11 4950 3488 46677613
Cardiac murmur 26.52 21.15 16 4945 11388 46669713
Arrhythmia 26.50 21.15 25 4936 34816 46646285
Arteriosclerosis coronary artery 25.83 21.15 14 4947 8142 46672959
Product use in unapproved indication 25.38 21.15 39 4922 90234 46590867
Bacterial disease carrier 24.43 21.15 7 4954 741 46680360
Organising pneumonia 23.08 21.15 11 4950 4891 46676210
Emphysema 21.82 21.15 13 4948 9041 46672060
Infective exacerbation of chronic obstructive airways disease 21.29 21.15 7 4954 1173 46679928

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic obstructive pulmonary disease 281.81 17.88 162 7196 45964 29899156
Dyspnoea 202.01 17.88 320 7038 332975 29612145
Cough 95.82 17.88 135 7223 125507 29819613
Emphysema 85.16 17.88 43 7315 9359 29935761
Productive cough 73.46 17.88 60 7298 29893 29915227
General physical health deterioration 61.18 17.88 97 7261 99847 29845273
Lymph node calcification 59.07 17.88 13 7345 195 29944925
Asthma 57.98 17.88 57 7301 36117 29909003
Lung neoplasm malignant 54.13 17.88 38 7320 15094 29930026
Wheezing 48.18 17.88 48 7310 30890 29914230
Pneumonia 45.64 17.88 182 7176 334124 29610996
Cardiac failure 44.32 17.88 76 7282 83342 29861778
Bronchial disorder 44.10 17.88 14 7344 900 29944220
Bronchial obstruction 41.22 17.88 15 7343 1461 29943659
Secretion discharge 39.33 17.88 19 7339 3756 29941364
Chest discomfort 39.25 17.88 52 7306 45428 29899692
Rheumatoid nodule 39.24 17.88 15 7343 1675 29943445
Lung disorder 38.60 17.88 43 7315 31426 29913694
Haemoptysis 35.63 17.88 41 7317 31037 29914083
Dyspnoea exertional 34.48 17.88 43 7315 35387 29909733
Concomitant disease aggravated 33.84 17.88 19 7339 5110 29940010
Choking 31.76 17.88 18 7340 4928 29940192
Idiopathic pulmonary fibrosis 29.38 17.88 16 7342 4053 29941067
Mesenteric vein thrombosis 29.33 17.88 9 7349 517 29944603
Drug intolerance 26.33 17.88 43 7315 45248 29899872
Bronchitis 23.90 17.88 38 7320 39087 29906033
Product use issue 21.91 17.88 40 7318 45976 29899144
Malaise 21.91 17.88 90 7268 166872 29778248
Arrhythmia 19.96 17.88 32 7326 33137 29911983
Incarcerated hernia 18.58 17.88 5 7353 179 29944941
Pneumothorax 17.94 17.88 21 7337 16172 29928948

Pharmacologic Action:

SourceCodeDescription
ATC R03AC18 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Selective beta-2-adrenoreceptor agonists
ATC R03AK14 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03AL04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL12 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA MoA N0000009922 Adrenergic beta2-Agonists
FDA EPC N0000175779 beta2-Adrenergic Agonist
CHEBI has role CHEBI:35522 beta-adrenergic receptor agonist
CHEBI has role CHEBI:35523 bronchodilator agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Prevention of Bronchospasm with Chronic Bronchitis indication
Prevention of Bronchospasms with Emphysema indication
Bronchospasm Prevention with COPD indication
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Conduction disorder of the heart contraindication 44808001
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Thyrotoxicosis contraindication 90739004 DOID:7997
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Exacerbation of asthma contraindication 281239006
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Congenital long QT syndrome contraindication 442917000
Acutely Deteriorating Chronic Obstructive Pulmonary Disease contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.25 acidic
pKa2 11.06 acidic
pKa3 13.25 acidic
pKa4 9.04 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST Ki 7.80 CHEMBL CHEMBL
Beta-1 adrenergic receptor GPCR Ki 7.04 CHEMBL
D(2) dopamine receptor GPCR IC50 4.60 CHEMBL
D(3) dopamine receptor GPCR Ki 5.98 CHEMBL
Beta-2 adrenergic receptor GPCR IC50 8.10 CHEMBL

External reference:

IDSource
4030903 VUID
N0000182968 NUI
D09318 KEGG_DRUG
753498-25-8 SECONDARY_CAS_RN
4030903 VANDF
C3195073 UMLSCUI
CHEBI:68573 CHEBI
CHEMBL1789842 ChEMBL_ID
CHEMBL1095777 ChEMBL_ID
DB05039 DRUGBANK_ID
9827599 PUBCHEM_CID
C510790 MESH_SUPPLEMENTAL_RECORD_UI
7455 IUPHAR_LIGAND_ID
8457 INN_ID
8OR09251MQ UNII
1114325 RXNORM
184350 MMSL
27231 MMSL
30721 MMSL
d07651 MMSL
013439 NDDF
013440 NDDF
702801003 SNOMEDCT_US
702802005 SNOMEDCT_US
703740005 SNOMEDCT_US

Pharmaceutical products:

None